On January 1, Janet B. McGill, MD, MA, FACP, and collaborators had their work titled “Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial” published in “Diabetes Technology and Therapeutics.”
The focus was “to evaluate safety and effectiveness of MiniMed™ 670G hybrid closed loop (HCL) in comparison with continuous subcutaneous insulin infusion (CSII) therapy for 6 months in persons with type 1 diabetes (T1D).”
The approach consisted of assessing adults, adolescents and children with T1D who were using CSII therapy and were enrolled and randomized to 6 months of HCL intervention or CSII without continuous glucose monitoring.
Their findings from the trial indicate that “the MiniMed 670G HCL safely and significantly improved A1C and %TBR <70 mg/dL compared with CSII control in persons with T1D, irrespective of baseline A1C level.”